Reversal of the neuroleptanalgesic effect of droperidolfentanyl in the dog by 4-aminopyridine and naloxone.
D015761:4-Aminopyridine; D000631:Aminopyridines / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology; D004329:Droperidol / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects; D015016:Yohimbine / Q000494:pharmacology
D000631:Aminopyridines; D002317:Cardiovascular Agents; D000697:Central Nervous System Stimulants; D004338:Drug Combinations; D015016:Yohimbine; D009270:Naloxone; D015761:4-Aminopyridine; D004329:Droperidol; D005283:Fentanyl